Phase 2a Study of SRSD107 Given by Injection in Adults With Chronic Coronary or Peripheral Arterial Disease

What this Trial Is About

Researchers are evaluating the effects of SRSD107 in adults with chronic coronary artery disease CAD andor peripheral arterial disease PAD. This Phase 2a study aims to understand how multiple doses of SRSD107 affect the body pharmacodynamics, how the body processes the drug pharmacokinetics, and its safety when used alongside aspirin therapy. The trial uses a randomized, double-blind, placebo-controlled design with several sequential groups to carefully assess these factors. Participants will receive subcutaneous injections of SRSD107 at different dose levels or a placebo. The study includes five groups four experimental dose levels of SRSD107 and one placebo group. All treatments are administered under close monitoring to assess drug levels and effects over time. Throughout the 72-week study period, participants will have regular assessments including blood tests to measure FXI antigen levels, FXI activity, and clotting times aPTT. Researchers will also track how much SRSD107 is present in the blood, the timing of peak concentrations, and any adverse events. Safety and drug effects will be carefully monitored to understand how SRSD107 works in this patient population.

A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease